8-K: HealthEquity Reports Strong Q2 Growth, Raises FY26 Outlook

HealthEquity, Inc. announced robust second-quarter fiscal year 2026 financial results, featuring significant revenue and profit growth, alongside an increase in HSA assets and accounts.

Summary

• Revenue for the second quarter ended July 31, 2025, increased by 9% to $325.8 million, up from $299.9 million in Q2 FY25.
• Net income surged by 67% to $59.9 million, compared to $35.8 million in the prior year's second quarter.
• Non-GAAP net income rose 24% to $94.6 million, up from $76.3 million in Q2 FY25.
• Diluted net income per share increased by 70% to $0.68, while non-GAAP diluted net income per share grew 26% to $1.08.
• Adjusted EBITDA reached $151.1 million, an 18% increase year-over-year, representing 46% of revenue.
• The company reported a record gross margin of 71%.
• Health Savings Accounts (HSAs) grew 6% year-over-year to 10.0 million, with total HSA assets increasing 12% to $33.1 billion.
• Total Accounts, including HSAs and complementary Consumer-Directed Benefits (CDBs), increased 5% to 17.1 million.
• The company repurchased 0.7 million shares of its common stock for $66.0 million during the quarter, with $351.8 million remaining authorized for repurchase.

Sentiment

Score: 9

Explanation: The filing indicates exceptionally strong financial and operational performance, with significant year-over-year growth across all key metrics, record gross margin, and a positive outlook. Management's comments reinforce confidence in future growth, supported by legislative tailwinds. The stock repurchase program further adds to positive sentiment.

Positives

• Revenue increased by 9% to $325.8 million, demonstrating strong top-line growth.
• Net income grew significantly by 67% to $59.9 million, indicating improved profitability.
• Non-GAAP net income increased by 24% to $94.6 million, reflecting strong operational performance.
• Diluted net income per share rose by 70% to $0.68, and non-GAAP diluted net income per share increased by 26% to $1.08.
• Adjusted EBITDA increased by 18% to $151.1 million, with Adjusted EBITDA as a percentage of revenue improving to 46% from 43%.
• Achieved a record gross margin of 71%, highlighting efficient cost management.
• HSAs grew 6% year-over-year to 10.0 million, reinforcing market leadership.
• Total HSA Assets increased 12% year-over-year to $33.1 billion, indicating strong asset accumulation.
• HSAs with investments grew 10% year-over-year to 782,000, showing increased engagement with investment options.
• Total Accounts increased 5% year-over-year to 17.1 million, reflecting broader customer acquisition.
• The company repurchased $66.0 million of common stock, signaling confidence in its valuation and returning value to shareholders.
• Management expressed optimism for the future, citing legislative expansion of HSAs since 2006.

Risks

• Ability to adequately place and safeguard custodial assets, or the failure of any depository or insurance company partners.
• Ability to compete effectively in a rapidly evolving healthcare and benefits administration industry.
• Dependence on the continued availability and benefits of tax-advantaged HSAs and other consumer-directed benefits (CDBs).
• Risks relating to the recent CEO transition.
• Impact of increased fraudulent account activity involving member accounts or third-party service providers on reputation and financial results.
• Ability to successfully identify, acquire, and integrate additional portfolio purchases or acquisition targets.
• Significant competition, including from those with greater resources.
• Reliance on the availability and performance of technology and communications systems.
• Recent and potential future cybersecurity breaches of technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage, and loss of business.
• The current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations.
• Potential regulatory changes and changes in the enforcement environment under the new U.S. administration.
• Ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser, and other laws applicable to the business.
• Reliance on partners and third-party vendors for distribution and important services.
• Ability to develop and implement updated features for technology platforms and communications systems.
• Reliance on the management team and key team members.

Future Outlook

For the fiscal year ending January 31, 2026, management expects revenues between $1.290 billion and $1.310 billion. Net income is projected to be between $185 million and $200 million, resulting in diluted net income per share of $2.11 to $2.28. Non-GAAP net income is anticipated to be between $329 million and $344 million, with non-GAAP diluted net income per share of $3.74 to $3.91. Adjusted EBITDA is expected to range from $540 million to $560 million.

Management Comments

• Scott Cutler, President and CEO: "The HealthEquity team delivered continued momentum during our second quarter with strong 9% revenue growth, record gross margin of 71% and record adjusted EBITDA of $151 million."
• Scott Cutler, President and CEO: "We believe our outlook is even brighter with our national lawmakers providing the largest legislative expansion of HSAs since 2006 as more American families seek access to the financial security and tax benefits that they provide. Through our proprietary technologies and platforms, Team Purple continues to empower a growing number of savvy healthcare consumers with tools and resources that drive better member outcomes."

Industry Context

HealthEquity's strong performance aligns with broader trends favoring consumer-directed healthcare and tax-advantaged savings vehicles. The CEO's comments highlight recent legislative expansion of HSAs, suggesting a supportive regulatory environment that could further accelerate growth in the sector. The increasing adoption of HSAs and other CDBs reflects a shift towards greater individual responsibility and control over healthcare finances, a trend HealthEquity is well-positioned to capitalize on with its platform and services.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, and a stock repurchase program, which could lead to increased share value.
• Customers (HSA members): Continued growth in accounts and assets, along with management's focus on empowering healthcare consumers, suggests ongoing value and service improvements.
• Employees: Strong company performance and growth typically indicate job stability and potential for growth opportunities.
• Partners and third-party vendors: Continued reliance on these entities suggests ongoing business relationships and potential for mutual growth.

Next Steps

• HealthEquity management will host a conference call on September 2, 2025, at 4:30 pm (Eastern Time) to discuss the fiscal 2026 second quarter financial results.

Key Dates

Recommendation

The filing presents exceptionally strong financial results, with significant year-over-year growth in revenue, net income, EPS, and Adjusted EBITDA. The company achieved a record gross margin and demonstrated robust growth in HSA accounts and assets. The positive business outlook for FY26, coupled with management's confidence in legislative tailwinds for HSAs, suggests continued strong performance. The ongoing stock repurchase program further enhances shareholder value. These factors collectively indicate a compelling investment opportunity.

Keywords

Health Savings Account, HSA, Consumer-Directed Benefits, CDB, Financial Results, Earnings, HealthEquity, HQY, Healthcare Finance, Custodial Assets, Adjusted EBITDA, Stock Repurchase